Find a Clinical Trial

Showing 1 - 2 of 2 Trials
  • Principal Investigator:

    David P. Horowitz, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    II
    This study is being done to answer the following question: Is using a lower-dose regimen of chemoradiation therapy as effective and does it have fewer side effects, compared to the standard-dose regimen of chemoradiation therapy for patients with anal cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your anal cancer. There is not an established treatment that is individualized for patients with early-stage anal cancer. However, the usual approach is defined as care most people get for anal cancer. Are you Eligible? (...
  • Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    GEN-011 is an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, the cancer proteins that are already recognized by the patient's T cells are found. Then, immune cells that recognize these cancer proteins are multiplied many times to create the GEN-011 cell therapy. The personalized GEN-011 is then given back to the patient in one or more intravenous (IV - into the vein) infusions. Are you Eligible? (Inclusion Criteria) Diagnosis of one of the...